Thus, this study will be the first to evaluate the cost-effectiveness of using brigatinib followed by lorlatinib before chemotherapy compared to reserving these two drugs until progression after chemotherapy for individuals with ALK-positive advanced NSCLC from the perspective of United States payers. Here, ALK is linked to non-small cell lung carcinoma.